In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Anavex Life Sciences (AVXL - Research Report), with a price target of $42.00. The company's shares closed yesterday at $10.80.Selvaraju covers the Healthcare sector, focusing on stocks such as Regulus, Aeterna Zentaris, and Oncternal Therapeutics. According to TipRanks, Selvaraju has an average return of -34.4% and a 19.35% success rate on recommended stocks. Anavex Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $35.20, which is a 225.93% upside from current levels.
https://www.tipranks.com/news/blurbs/anavex-life-sciences-avxl-receives-a-buy-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Anavex Life Sciences Charts.
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Anavex Life Sciences Charts.